✓ Last verified: March 10, 2026 — Edited & verified by Angelica Bottaro for HealingMaps Editorial Staff
Known For: Richmond’s most insurance-accessible advanced depression treatment center, offering REMS-certified Spravato and NeuroStar TMS with dedicated care coordinators who handle prior authorizations. Accepts Medicaid — rare for ketamine-adjacent treatment.
| Review Scores | Growing reputation; patients appreciate the insurance-friendly model and personalized care |
| Location | North Chesterfield, VA |
| Address | 11600 Busy Street, Suite 203, North Chesterfield, VA 23236 |
| Phone | (804) 506-0526 |
| Website | foundationmedicalgroup.org |
| Treatments | Spravato (Esketamine Nasal Spray), NeuroStar TMS Therapy, Quantitative EEG Brain Mapping, GeneSight Pharmacogenetic Testing, Psychiatric Services |
| Conditions Treated | Treatment-Resistant Depression, Major Depressive Disorder, MDD with Suicidal Ideation |
| Cost | Spravato and TMS typically covered by insurance; contact for details |
| Insurance | Accepts Anthem, Aetna, Cigna, UnitedHealthcare, Optima, Medicare, Virginia Medicaid |
| Clinical Lead | Dr. Vincent Nardone, MD — Physician and practice founder |
💡 No clinic-specific pricing posted? See our ketamine therapy cost guide for typical pricing ranges by treatment type and insurance pathways.
HealingMaps Take: Foundation Medical Group is quietly building one of the most accessible advanced depression treatment programs in the Richmond metro. What sets them apart is not clinical flash but insurance infrastructure: they accept Anthem, Aetna, Cigna, UnitedHealthcare, Optima, Medicare, and — critically — Virginia Medicaid. That Medicaid acceptance is a genuine differentiator in the ketamine/esketamine space, where most providers are cash-only and a six-infusion series can run $3,000+. Foundation’s dedicated care coordinators handle prior authorizations and copay assistance, removing the administrative barrier that stops many patients from ever starting Spravato treatment. The clinic is REMS-certified (required for Spravato dispensing) and offers private treatment suites with continuous vital monitoring during the two-hour observation period. The addition of GeneSight pharmacogenetic testing is smart — it helps identify which patients are true non-responders to traditional antidepressants (and thus genuine Spravato candidates) versus patients who were simply on the wrong medication. The practice is also expanding into IV and IM ketamine, which would make them a full-spectrum provider. For patients — especially those on Medicaid or limited insurance — who need advanced depression treatment, Foundation is removing the barriers that other clinics have not addressed.
Market Position: Foundation Medical Group is a Spravato-certified clinic in the Chesterfield metro. Spravato (esketamine) is the FDA-approved ketamine treatment that most commercial insurance plans cover after prior authorization — unlike cash-pay IV ketamine.
Industry pricing reference. Foundation Medical Group has not published specific per-session pricing — contact the clinic directly for a quote. The calculator above shows typical metro-level cost estimates across protocols, not this clinic’s specific prices.
| Protocol | Typical Industry Cost | Offered Here |
|---|---|---|
| IV Ketamine | $350–$650/session | — |
| Spravato (esketamine) | $0–$250 copay (insured) | ✓ Yes |
| IM Ketamine | $250–$400/injection | — |
| KAP (with therapist) | $400–$1,200/session | — |
| At-home troches | $150–$300/month | — |
This 2-question summary is matched to the protocols and conditions Foundation Medical Group treats. Editorial responses are HealingMaps-authored, grounded in our 2026 Ketamine Clinic Intelligence Report.
Yes — Foundation Medical Group offers Spravato, which means they’re FDA REMS-certified and maintain the required two-hour in-office monitoring window after each dose. Spravato is the primary insurance-covered ketamine option for treatment-resistant depression. Worth confirming the prior-authorization timeline before booking your first session.
Foundation Medical Group treats depression via Spravato (FDA-approved for TRD). The Spravato pathway is the most likely to obtain commercial insurance coverage. TRD is typically defined as two or more prior antidepressant trials without sufficient response — patients meeting that bar are best candidates here.
Leave a Reply